Farms.com Home   News

Long-Term Cost of Respiratory Disease during Weaning and Backgrounding

Weekly, Oklahoma State University Extension Beef Cattle Nutrition Specialist Paul Beck offers his expertise on the beef cattle industry. This is a part of the weekly series known as the "Cow-Calf Corner" published electronically by Beck. Today, he talks about the implications of respiratory disease.


Health of incoming cattle to backgrounders and feedlots continues to be a major issue. Today we have better vaccines, better antibiotics, and better genetics than ever before, but the health outcomes, sick pull rates and mortality, have not improved over the last 30 years. Many times, disease infections can occur in one segment of the industry but not present clinically until the cattle are stressed during transfer to a subsequent beef production segment in the supply chain.

An analysis of the performance and carcass quality costs of bovine respiratory disease during finishing conducted at Oklahoma State University showed that days on feed increased while slaughter weight, carcass weights, and carcass quality decreased when steers required BRD treatment once, twice, or three or more times during receiving. Hot carcass weights of cattle three or more times were 42 pounds lighter than carcasses from calves that did not require treatment. The percentage choice decreased from 70% for untreated calves to 36% for calves treated 3 or more times. Total cost of BRD (including labor, cost of antibiotic, reduced production and carcass quality, and increased days of feed) was $37/head, $166/head, and $230/head for cattle treated once, twice, and three or more times.

Costs in the stocker industry can be just as big. An analysis was conducted including 12 stocker receiving trials from Oklahoma, Arkansas and Mississippi where over 1,300 steers and bulls were received and followed through grazing on cool-season pastures. The average BRD morbidity was 57% with 25% requiring a second treatment and 9.5% pulled and treated three or more times. During receiving, untreated calves gained 2.3 pounds per day, daily gains decreased to 2.1, 1.6, and 1.5 pounds/day for calves treated once, twice, or three or more times. Daily gains on pasture were not affected for calves treated only once (2.2 lbs/day), yet pasture gains of calves treated 2 or more times decreased to 2.0 lbs/day. During the entire ownership period (Receiving + Grazing) daily gains were 2.3 pounds for untreated, 2.1 for those treated once, 1.8 for those treated twice, and 1.7 for those treated three or more times. These calves appeared healthy when placed on grass, chronics (any calves that appeared to be chronically morbid to BRD) were not included in this analysis. Even yet, calves that were treated for BRD two or more times were affected significantly during grazing and over the ownership period.

Click here to see more...

Trending Video

New Solution Powers Efficient Pork Growth

Video: New Solution Powers Efficient Pork Growth


Alltech has introduced Olerix, an innovative phytogenic blend created to promote growth and feed efficiency in pigs. Through a proprietary coating process, the bioactive blend of phytogenic compounds used in Olerix is designed to outlast the manufacturing process, ensuring consistent outcomes from feed to finish. The result is a high-impact efficiency solution that provides consistent support for gut health, feed efficiency, immune function and growth performance. Olerix is backed by validated trials conducted under modern pork production conditions.

“As the industry searches for technology to drive profitability forward in a more sustainable manner, we’re thrilled to join that effort with our Olerix technology,” said Mark Hulsebus, general manager for U.S. pork at Alltech. “Our work in this phytogenic space is yielding very encouraging results, and we’re excited to make this new opportunity available to pork producers focused on optimizing feed efficiency and growth rates.”

“Olerix represents the next generation of phytogenic technology — combining feed efficiency, livability and immune support into a practical commercial solution producers can implement today,” said Andy Rash, U.S. monogastric director at Alltech.